372 related articles for article (PubMed ID: 28460885)
1. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.
Sanders DB; Solomon GM; Beckett VV; West NE; Daines CL; Heltshe SL; VanDevanter DR; Spahr JE; Gibson RL; Nick JA; Marshall BC; Flume PA; Goss CH;
J Cyst Fibros; 2017 Sep; 16(5):592-599. PubMed ID: 28460885
[TBL] [Abstract][Full Text] [Related]
2. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations.
West NE; Beckett VV; Jain R; Sanders DB; Nick JA; Heltshe SL; Dasenbrook EC; VanDevanter DR; Solomon GM; Goss CH; Flume PA;
J Cyst Fibros; 2017 Sep; 16(5):600-606. PubMed ID: 28457954
[TBL] [Abstract][Full Text] [Related]
3. Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations.
Al-Aloul M; Nazareth D; Walshaw M
J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):299-305. PubMed ID: 24219814
[TBL] [Abstract][Full Text] [Related]
4. Antibiotic treatment of signs and symptoms of pulmonary exacerbations: a comparison by care site.
Schechter MS; Regelmann WE; Sawicki GS; Rasouliyan L; VanDevanter DR; Rosenfeld M; Pasta D; Morgan W; Konstan MW
Pediatr Pulmonol; 2015 May; 50(5):431-40. PubMed ID: 25530325
[TBL] [Abstract][Full Text] [Related]
5. Predictors of pulmonary exacerbation treatment in cystic fibrosis.
Sanders DB; Ostrenga JS; Rosenfeld M; Fink AK; Schechter MS; Sawicki GS; Flume PA; Morgan WJ
J Cyst Fibros; 2020 May; 19(3):407-414. PubMed ID: 31257102
[TBL] [Abstract][Full Text] [Related]
6. Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.
Ryan G; Jahnke N; Remmington T
Cochrane Database Syst Rev; 2012 Dec; 12():CD008319. PubMed ID: 23235659
[TBL] [Abstract][Full Text] [Related]
7. IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis.
VanDevanter DR; Morris NJ; Konstan MW
J Cyst Fibros; 2016 May; 15(3):372-9. PubMed ID: 26603642
[TBL] [Abstract][Full Text] [Related]
8. Antibiotic duration and changes in FEV
Espel JC; Palac HL; Cullina JF; Clarke AP; McColley SA; Prickett MH; Jain M
BMC Pulm Med; 2017 Nov; 17(1):160. PubMed ID: 29187171
[TBL] [Abstract][Full Text] [Related]
9. A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients.
Flume PA; VanDevanter DR; Morgan EE; Dudley MN; Loutit JS; Bell SC; Kerem E; Fischer R; Smyth AR; Aaron SD; Conrad D; Geller DE; Elborn JS
J Cyst Fibros; 2016 Jul; 15(4):495-502. PubMed ID: 26852040
[TBL] [Abstract][Full Text] [Related]
10. Continuous alternating inhaled antibiotic therapy in CF: A single center retrospective analysis.
Van de Kerkhove C; Goeminne PC; Kicinski M; Nawrot TS; Lorent N; Van Bleyenbergh P; De Boeck K; Dupont LJ
J Cyst Fibros; 2016 Nov; 15(6):802-808. PubMed ID: 27720321
[TBL] [Abstract][Full Text] [Related]
11. Reduction in Pseudomonas aeruginosa sputum density during a cystic fibrosis pulmonary exacerbation does not predict clinical response.
Lam JC; Somayaji R; Surette MG; Rabin HR; Parkins MD
BMC Infect Dis; 2015 Mar; 15():145. PubMed ID: 25887462
[TBL] [Abstract][Full Text] [Related]
12. Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection.
Greenwood J; Schwarz C; Sommerwerck U; Nash EF; Tamm M; Cao W; Mastoridis P; Debonnett L; Hamed K
Ther Adv Respir Dis; 2017 Jul; 11(7):249-260. PubMed ID: 28614995
[TBL] [Abstract][Full Text] [Related]
13. Oral Azithromycin and Response to Pulmonary Exacerbations Treated with Intravenous Tobramycin in Children with Cystic Fibrosis.
Klingel M; Stanojevic S; Tullis E; Ratjen F; Waters V
Ann Am Thorac Soc; 2019 Jul; 16(7):861-867. PubMed ID: 30874447
[No Abstract] [Full Text] [Related]
14. Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): A trial to compare intravenous antibiotic treatment durations in CF.
Heltshe SL; West NE; VanDevanter DR; Sanders DB; Beckett VV; Flume PA; Goss CH;
Contemp Clin Trials; 2018 Jan; 64():35-40. PubMed ID: 29170074
[TBL] [Abstract][Full Text] [Related]
15. The effect of oral and intravenous antimicrobials on pulmonary exacerbation recovery in cystic fibrosis.
VanDevanter EJ; Heltshe SL; Skalland M; Lechtzin N; Nichols D; Goss CH
J Cyst Fibros; 2021 Nov; 20(6):932-936. PubMed ID: 33685776
[TBL] [Abstract][Full Text] [Related]
16. Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis.
Heltshe SL; Goss CH; Thompson V; Sagel SD; Sanders DB; Marshall BC; Flume PA
Thorax; 2016 Mar; 71(3):223-9. PubMed ID: 25911223
[TBL] [Abstract][Full Text] [Related]
17. Antibiotics and outcomes of CF pulmonary exacerbations in children infected with MRSA and Pseudomonas aeruginosa.
Cogen JD; Hall M; Faino AV; Ambroggio L; Blaschke AJ; Brogan TV; Cotter JM; Gibson RL; Grijalva CG; Hersh AL; Lipsett SC; Shah SS; Shapiro DJ; Neuman MI; Gerber JS
J Cyst Fibros; 2023 Mar; 22(2):313-319. PubMed ID: 35945130
[TBL] [Abstract][Full Text] [Related]
18. Rationalizing endpoints for prospective studies of pulmonary exacerbation treatment response in cystic fibrosis.
VanDevanter DR; Heltshe SL; Spahr J; Beckett VV; Daines CL; Dasenbrook EC; Gibson RL; Raksha J; Sanders DB; Goss CH; Flume PA;
J Cyst Fibros; 2017 Sep; 16(5):607-615. PubMed ID: 28438499
[TBL] [Abstract][Full Text] [Related]
19. Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials.
Haworth CS; Bilton D; Chalmers JD; Davis AM; Froehlich J; Gonda I; Thompson B; Wanner A; O'Donnell AE
Lancet Respir Med; 2019 Mar; 7(3):213-226. PubMed ID: 30658914
[TBL] [Abstract][Full Text] [Related]
20. Antibiotic perturbation of mixed-strain Pseudomonas aeruginosa infection in patients with cystic fibrosis.
Tai AS; Sherrard LJ; Kidd TJ; Ramsay KA; Buckley C; Syrmis M; Grimwood K; Bell SC; Whiley DM
BMC Pulm Med; 2017 Nov; 17(1):138. PubMed ID: 29096618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]